Updated Aug 7 at 7:02pm ET.
Follow Inspire Medical Systems to never miss an important update.
Analysts at Oppenheimer raised their rating on the stock to Outperform, setting a price target of $85. This suggests they see significant room for the stock to rise from its current price near $60.
The upgrade follows a strong quarterly report where the company beat expectations and raised its full-year outlook. While other firms remained neutral, this move reflects growing confidence that the company can maintain its growth as it rolls out its next-generation sleep apnea device.
Source: Oppenheimer
The company reported adjusted earnings of $0.14 per share, easily beating the loss analysts expected. Revenue grew to about $201 million, also coming in ahead of forecasts. Management raised its outlook for the rest of the year, signaling confidence in its ability to navigate changes in how medical procedures are coded and paid for by insurers.
Beyond the numbers, the company launched a plan to find $30 million in savings to reinvest in growth. For long-term owners, the key takeaway is that the business is showing it can grow profitably even as it works through the launch of its new Inspire V device. It also generated $23 million in cash from its operations, further strengthening its financial footing.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Kahn Swick & Foti is continuing an investigation into whether company leaders provided accurate information about the launch of the Inspire V device. The firm points to a 2025 disclosure that the launch would take longer than previously suggested. These types of investigations by law firms are common after a stock price drop or a delayed product launch. Unless they lead to a formal lawsuit with specific evidence of wrongdoing, they rarely have a material impact on the business.
Source: Business Wire
Michael Carrel, an experienced executive in the medical device industry, has joined the board of directors. He currently serves as the CEO of AtriCure, a company that treats heart rhythm disorders. Adding a sitting CEO with deep experience in specialized medical technology is a routine but positive step for the board's oversight.
Source: 8-K filing
Casey Tansey has retired from the board of directors after serving for nearly two decades. His departure was effective July 30. This appears to be a standard retirement for a long-tenured director and does not suggest any disagreement with the company's direction.
Source: 8-K filing
Analysts issued a flurry of price target increases following the company's strong second-quarter earnings report. Most analysts are split, with 11 of 27 rating the stock a buy, and the average target of $61 is roughly equal to today's price.
The company has a perfect record of beating analyst profit targets over the last two years. Management consistently sets a bar they can clear, making their financial forecasts feel reliable.
| Expectation | |
|---|---|
| EPS | $0.11 |
| Revenue | $204M |
Seeking Alpha · Opinion · Aug 4
GlobeNewsWire · Press release · Aug 3
GlobeNewsWire · Press release · Jul 27
Business Wire · Press release · Jul 24
Follow Inspire Medical Systems to get the latest and most important updates.
Follow INSP